Global Search | Novartis

Hide Filters

Sort by

Relevance

Newest first

Oldest first

Showing 2663 results

Media Release / Apr 24, 2017
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada
Novartis and Amgen to co-commercialize AMG 334 (erenumab) in the US; Novartis to gain exclusive rights in Canada Novartis retains commercial rights in rest of world; Amgen retains commercial…
Media Release / Apr 24, 2017
Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS
Over 16 months, more than 75% of patients on Gilenya had either no relapses, no new or enlarged MRI lesions or no disability progression; around 58% showed brain shrinkage levels broadly within the…
Media Release / Apr 25, 2017
Novartis erzielt Umsatzsteigerungen in allen Divisionen (kWk1), wobei Wachstumstreiber wie Cosentyx und Entresto die Einbussen durch Generika mehr als wettmachen; Innovationsdynamik setzt sich fort
Der Nettoumsatz wächst um 2% (kWk, -1% USD), da die Wachstumstreiber die Einbussen bei Glivec/Gleevec mehr als wettmachen Cosentyx (USD 410 Millionen, +136% kWk) erzielt in allen drei Indikationen…
Media Release / Apr 25, 2017
Novartis: ventes en progression (tcc1) dans toutes ses divisions; les moteurs de croissance, Cosentyx et Entresto inclus, compensent l'érosion due aux génériques; l'innovation toujours en plein essor
Chiffre d'affaires net en hausse de 2% (tcc, -1% en USD), car les moteurs de croissance ont plus que compensé l'impact de Gleevec/Glivec Cosentyx (USD 410 millions, +136% tcc):…
Media Release / Apr 25, 2017
Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
Net sales grew 2% (cc, -1% USD), as growth drivers more than offset Gleevec/Glivec impact Cosentyx (USD 410 million, +136% cc) showing strong growth in all three indications Entresto (USD 84…
Media Release / Apr 28, 2017
Novartis receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM)
Approval in newly diagnosed FLT3-mutated AML represents the first new treatment in more than 25 years[1],[2] Rydapt treatment regimen in FLT3-mutated AML demonstrated a significant improvement…
Media Release / Apr 26, 2017
Alcon announces EU launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma
Now available in the UK, Germany, Italy and Spain, CyPass Micro-Stent is designed to significantly reduce intraocular pressure (IOP) CE indication has been expanded to allow patients to be…
Media Release / May 11, 2017
Novartis celebrates 21st annual Community Partnership Day with over 24,500 associates volunteering in their local communities
Community Partnership Day symbolizes the company's commitment to improving people's lives and serving our local communities Follow the excitement with #NovartisCPD2017 and #proudmoments2017 via…
Media Release / May 04, 2017
Novartis exercises exclusive option agreement with Conatus for the treatment of NASH
Exclusive license for emricasan supports rapidly growing development portfolio in chronic liver diseases, including NASH Conatus has initiated the Phase IIb ENCORE-LF clinical trial with…
Media Release / May 18, 2017
Novartis data at ASCO, ICML and EHA meetings demonstrate meaningful advancements in cancer care
Updated analyses from the Kisqali® pivotal Phase III MONALEESA-2 trial in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer to be…